Elucidation of expression mechanism of novel immunomodulators for prevention of metastasis

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09191
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56010:Neurosurgery-related
• Research Institution: Kansai Medical University
• Principal Investigator: IWATA Ryoichi 関西医科大学, 医学部, 非常勤講師 (60580446)
• Co-Investigator(Kenkyū-buntansha): 林 美樹夫 関西医科大学, 医学部, 講師 (10368251)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 脳転移 / がん

Outline of Final Research Achievements

The standard treatment for metastatic brain tumors is surgical resection and radiation therapy, but the prognosis for patients is poor. The existence of cancer stem cells has been proposed as a source of cancer development and treatment resistance. In this study, we found the expression of ICOSLG, a regulatory T cell regulator, in lung cancer brain metastases and their cancer stem cells. These results suggest that ICSLG may be a potential therapeutic target for metastatic brain tumors.

Free Research Field

脳神経外科学

Academic Significance and Societal Importance of the Research Achievements

本邦における転移性脳腫瘍の罹患者数は年間数万人以上と推計されている。また、転移性脳腫瘍の半数を占める肺がんの国内患者数は11万人である。脳転移開始細胞を標的とする治療法は、がん再発予防法として広く波及すると期待できる。